NDAINTRAVENOUSPOWDER
Approved
Apr 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER (meropenem and sodium chloride) by B. Braun is 12. Approved for complicated skin, skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes and 14 more indications. First approved in 2015.
Drug data last refreshed 20h ago
Mechanism of Action
12.1 Mechanism of Action Meropenem is an antibacterial drug [see ]. 12.2 Pharmacodynamics The percentage of time of a dosing interval that unbound plasma concentration of meropenem exceeds the meropenem minimum inhibitory concentration (MIC) against the infecting organism has been shown to best…
Worked on MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.